Triana's platform aims to generate products that stabilize pre-existing or create de novo interactions between two proteins and alter the fate or functionality of the disease target. Molecular glues may allow for the pursuit of highly disease-relevant targets long considered undruggable or inadequately addressed by traditional drug discovery approaches.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
04/06/22	$110,000,000	Seed and Series A	Atlas Venture Logos Capital Pfizer Venture Investments RA Capital Management Surveyor Capital	undisclosed
12/03/25	$120,000,000	Series B	Ascenta Capital Atlas Venture Bessemer Venture Partners Finchley H.V. Invus Lightspeed Venture Partners Pfizer Venture Investments RA Capital Management Regeneron Ventures Surveyor Capital YK Bioventures	undisclosed